CA2785038A1 - Bmp-7 variants with reduced immunogenicity - Google Patents
Bmp-7 variants with reduced immunogenicity Download PDFInfo
- Publication number
- CA2785038A1 CA2785038A1 CA2785038A CA2785038A CA2785038A1 CA 2785038 A1 CA2785038 A1 CA 2785038A1 CA 2785038 A CA2785038 A CA 2785038A CA 2785038 A CA2785038 A CA 2785038A CA 2785038 A1 CA2785038 A1 CA 2785038A1
- Authority
- CA
- Canada
- Prior art keywords
- bmp
- variant
- protein
- variants
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000005847 immunogenicity Effects 0.000 title claims abstract description 23
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 title description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims abstract description 165
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims abstract description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 21
- 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 claims abstract 11
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 238000006467 substitution reaction Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 20
- 102220477897 Protein phosphatase 1 regulatory subunit 12C_Y65F_mutation Human genes 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 14
- 102220068474 rs149348130 Human genes 0.000 claims description 14
- 102220005357 rs281864881 Human genes 0.000 claims description 14
- 102200029981 rs28936700 Human genes 0.000 claims description 14
- 102200124656 rs6267 Human genes 0.000 claims description 14
- 102220178774 rs745795470 Human genes 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 12
- 102220059500 rs786202847 Human genes 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 102220059219 rs786202857 Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 102000046107 human BMP7 Human genes 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 102220179352 rs371106978 Human genes 0.000 claims 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract description 25
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract description 25
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract description 24
- 230000004075 alteration Effects 0.000 abstract description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 154
- 108090000765 processed proteins & peptides Proteins 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 16
- 230000004927 fusion Effects 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 15
- 230000002188 osteogenic effect Effects 0.000 description 12
- 230000008468 bone growth Effects 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 10
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 10
- 102220277542 rs1553619417 Human genes 0.000 description 10
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 9
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000007429 general method Methods 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000000921 morphogenic effect Effects 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 4
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 description 4
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 4
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 3
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 3
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 3
- 102100035363 Growth/differentiation factor 7 Human genes 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 108010056852 Myostatin Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 102100037150 BMP and activin membrane-bound inhibitor homolog Human genes 0.000 description 2
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 2
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 2
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 2
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 2
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 2
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010061762 Chondropathy Diseases 0.000 description 2
- 208000003044 Closed Fractures Diseases 0.000 description 2
- 102100029379 Follistatin-related protein 3 Human genes 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 102100038353 Gremlin-2 Human genes 0.000 description 2
- 101710169778 Gremlin-2 Proteins 0.000 description 2
- 108010090250 Growth Differentiation Factor 6 Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 2
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 2
- 101710204283 Growth/differentiation factor 7 Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000740070 Homo sapiens BMP and activin membrane-bound inhibitor homolog Proteins 0.000 description 2
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 description 2
- -1 MP-52) Proteins 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 102000011830 Neural cell adhesion Human genes 0.000 description 2
- 108050002172 Neural cell adhesion Proteins 0.000 description 2
- 208000002565 Open Fractures Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 108010027904 cartilage-derived-morphogenetic protein-2 Proteins 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100025440 BMP-binding endothelial regulator protein Human genes 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 101710117970 Bone morphogenetic protein 8B Proteins 0.000 description 1
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 1
- 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 241000202252 Cerberus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100020921 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 101710204270 Growth/differentiation factor 2 Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 101000934632 Homo sapiens BMP-binding endothelial regulator protein Proteins 0.000 description 1
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 1
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101001023964 Homo sapiens Growth/differentiation factor 6 Proteins 0.000 description 1
- 101001023968 Homo sapiens Growth/differentiation factor 7 Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 description 1
- 101710169324 Sclerostin domain-containing protein 1 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000013860 dentinogenesis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000007941 heterotopic ossification Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 108091008597 receptor serine/threonine kinases Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002163 scaffold cell Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025934 tissue morphogenesis Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28922009P | 2009-12-22 | 2009-12-22 | |
| US61/289,220 | 2009-12-22 | ||
| PCT/US2010/061437 WO2011087768A1 (en) | 2009-12-22 | 2010-12-21 | Bmp-7 variants with reduced immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2785038A1 true CA2785038A1 (en) | 2011-07-21 |
Family
ID=43735952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2785038A Abandoned CA2785038A1 (en) | 2009-12-22 | 2010-12-21 | Bmp-7 variants with reduced immunogenicity |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130190236A1 (https=) |
| EP (1) | EP2516456A1 (https=) |
| JP (1) | JP2013514811A (https=) |
| CN (1) | CN102822197A (https=) |
| AU (1) | AU2010341565A1 (https=) |
| CA (1) | CA2785038A1 (https=) |
| WO (1) | WO2011087768A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432423A (zh) | 2014-09-26 | 2022-05-06 | 拉金德拉·萨哈伊·巴特纳格尔 | 用于治疗疾病和病症的NFkB活性的抑制剂 |
| US10130678B2 (en) | 2014-12-29 | 2018-11-20 | Bioventus, LLC. | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
| WO2019148140A2 (en) * | 2018-01-26 | 2019-08-01 | Wu Joseph C | Implantable biomaterials that enhance stem cell survival and function |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| JPH06500466A (ja) | 1990-06-15 | 1994-01-20 | カーネギー インスチチューション オブ ワシントン | Ｇｄｆ―１ |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5674844A (en) | 1991-03-11 | 1997-10-07 | Creative Biomolecules, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6800603B2 (en) | 1991-03-11 | 2004-10-05 | Curis, Inc. | Morphogen-induced neural cell adhesion |
| US5849686A (en) | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US6506729B1 (en) | 1991-03-11 | 2003-01-14 | Curis, Inc. | Methods and compositions for the treatment and prevention of Parkinson's disease |
| US6949505B1 (en) | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| DK0625989T3 (da) | 1992-02-12 | 2000-06-26 | Bioph Biotech Entw Pharm Gmbh | DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer |
| JPH08503198A (ja) | 1992-11-03 | 1996-04-09 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | Ｏｐ−３誘導形態形成 |
| JP3645258B2 (ja) | 1993-01-12 | 2005-05-11 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−５ |
| EP0678101A4 (en) | 1993-01-12 | 1997-07-16 | Univ Johns Hopkins Med | FACTOR-9 OF GROWTH AND DIFFERENTIATION. |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| BR9406715A (pt) | 1993-05-12 | 1996-02-06 | Genetics Inst | Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica |
| EP0698095B1 (en) | 1993-05-12 | 2004-04-28 | Genetics Institute, LLC | Bmp-10 compositions |
| CA2165776A1 (en) | 1993-07-09 | 1995-01-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-6 |
| EP0725796A4 (en) | 1993-10-08 | 1999-12-01 | Univ Johns Hopkins | Growth differentiation factor-10 |
| JP3300500B2 (ja) | 1993-10-12 | 2002-07-08 | 新日本製鐵株式会社 | 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法 |
| DE4334646C1 (de) | 1993-10-12 | 1994-09-29 | Quinting Friedhelm | Durchsichtige Analog-Zeituhr |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| DE69434651T2 (de) | 1993-12-07 | 2007-03-08 | Genetics Institute, Inc., Cambridge | Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen |
| IL114397A0 (en) | 1994-07-01 | 1995-10-31 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF-beta-family |
| CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
| WO1996014335A1 (en) | 1994-11-07 | 1996-05-17 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services | Cartilage-derived morphogenetic proteins |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| KR20000064752A (ko) | 1996-03-22 | 2000-11-06 | 더 제네랄 호스피탈 코포레이션 | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 |
| US6498142B1 (en) | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| US6958149B2 (en) | 1998-10-06 | 2005-10-25 | Stryker Corporation | Repair of larynx, trachea, and other fibrocartilaginous tissues |
| US6846906B1 (en) | 1998-10-07 | 2005-01-25 | Stryker Corporation | Modified proteins of the TGF-β superfamily, including morphogenic proteins |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| US6677432B1 (en) | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| US8154581B2 (en) | 2002-10-15 | 2012-04-10 | Revolutionary Concepts, Inc. | Audio-video communication system for receiving person at entrance |
| US8501424B2 (en) * | 2003-11-03 | 2013-08-06 | Danisco Us Inc. | Cd4+ epitopes of bone morphogenetic proteins |
| US7459527B2 (en) * | 2004-03-31 | 2008-12-02 | Xencor, Inc. | BMP-7 variants with improved properties |
| WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
| ES2369629T3 (es) | 2004-05-25 | 2011-12-02 | Stryker Corporation | Uso de op-1 para tratar defectos del cartílago. |
| WO2007087053A2 (en) | 2005-12-22 | 2007-08-02 | Centocor, Inc | Bmp-7 variant compositions, methods and uses |
| US7659250B2 (en) * | 2005-12-22 | 2010-02-09 | Centocor, Inc. | BMP-7 variant compositions, methods and uses |
| WO2008051526A2 (en) * | 2006-10-23 | 2008-05-02 | Stryker Corporation | Bone morphogenetic proteins |
| EP2222696A1 (en) * | 2007-12-21 | 2010-09-01 | Stryker Corporation | Bmp mutants with decreased susceptibility to noggin |
| WO2010117047A1 (ja) | 2009-04-10 | 2010-10-14 | 株式会社ニコン | 光学材料、光学素子、及びその製造方法 |
| JP2011211450A (ja) | 2010-03-30 | 2011-10-20 | Victor Co Of Japan Ltd | 立体映像表示装置、立体映像撮像装置および立体映像表示方法 |
| US9507084B2 (en) | 2010-12-03 | 2016-11-29 | Ofs Fitel, Llc | Single-mode, bend-compensated, large-mode-area optical fibers designed to accomodate simplified fabrication and tighter bends |
| US8886307B2 (en) | 2012-01-30 | 2014-11-11 | Medtronic, Inc. | Adaptive cardiac resynchronization therapy |
| WO2013183270A1 (ja) | 2012-06-07 | 2013-12-12 | 旭化成エレクトロニクス株式会社 | 位置検出装置 |
| US9298469B2 (en) | 2012-06-15 | 2016-03-29 | International Business Machines Corporation | Management of multiple nested transactions |
| US9405290B1 (en) | 2013-01-17 | 2016-08-02 | Kla-Tencor Corporation | Model for optical dispersion of high-K dielectrics including defects |
| JP6154215B2 (ja) | 2013-06-28 | 2017-06-28 | 株式会社日立国際電気 | 半導体装置の製造方法、基板処理装置およびプログラム |
| US9170581B2 (en) | 2013-09-30 | 2015-10-27 | Crown Equipment Limited | Industrial vehicles with overhead light based localization |
| JP6541301B2 (ja) | 2014-03-28 | 2019-07-10 | キヤノン株式会社 | ロボット装置、ロボット装置の制御方法、ロボット制御プログラム、及び記録媒体 |
| US9411440B2 (en) | 2014-08-22 | 2016-08-09 | Qualcomm Incorporated | Digital ultrasonic emitting base station |
| US9407762B2 (en) | 2014-10-10 | 2016-08-02 | Bank Of America Corporation | Providing enhanced user authentication functionalities |
| US9412814B2 (en) | 2014-12-24 | 2016-08-09 | Taiwan Semiconductor Manufacturing Co., Ltd. | Structure and formation method of FinFET device |
| US9400685B1 (en) | 2015-01-30 | 2016-07-26 | Huawei Technologies Co., Ltd. | Dividing, scheduling, and parallel processing compiled sub-tasks on an asynchronous multi-core processor |
-
2010
- 2010-12-21 WO PCT/US2010/061437 patent/WO2011087768A1/en not_active Ceased
- 2010-12-21 AU AU2010341565A patent/AU2010341565A1/en not_active Abandoned
- 2010-12-21 CA CA2785038A patent/CA2785038A1/en not_active Abandoned
- 2010-12-21 JP JP2012546131A patent/JP2013514811A/ja active Pending
- 2010-12-21 CN CN2010800643966A patent/CN102822197A/zh active Pending
- 2010-12-21 EP EP10801334A patent/EP2516456A1/en not_active Withdrawn
-
2013
- 2013-02-13 US US13/766,014 patent/US20130190236A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011087768A1 (en) | 2011-07-21 |
| EP2516456A1 (en) | 2012-10-31 |
| CN102822197A (zh) | 2012-12-12 |
| JP2013514811A (ja) | 2013-05-02 |
| AU2010341565A1 (en) | 2012-07-12 |
| US20130190236A1 (en) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5529754B2 (ja) | Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体 | |
| US7163920B2 (en) | Peptide with osteogenic activity | |
| US20140336114A1 (en) | Buffers for Controlling the pH of Bone Morphogenetic Proteins | |
| TW201226565A (en) | Designer osteogenic proteins | |
| US9200048B2 (en) | High activity growth factor mutants | |
| US20130190236A1 (en) | BMP-7 Variants with Reduced Immunogenicity | |
| US20110224138A1 (en) | Methods for treating pain induced by injuries and diseases of an articular joint | |
| US9012401B2 (en) | Growth factor mutants with improved biological activity | |
| AU2017200239B2 (en) | Designer osteogenic proteins | |
| Chen | Recombinant human morphogenetic protein: its future role in spinal fusions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20161221 |